Wyeth Receives Honors at the 2007 Sc... ( COLLEGEVILLE Pa. Dec. 5 /- WyethP...)

Wyeth Receives Honors at the 2007 Scrip Awards

Date:12/5/2007

COLLEGEVILLE, Pa., Dec. 5 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has been recognized for its leading scientific and pharmaceutical achievements at the third annual Scrip Awards ceremony held in London, England on December 4. Wyeth received honors for Best Overall Pipeline, and Best New Drug. The awards are given out by Scrip World Pharmaceutical News, a leading source of global business news in the pharmaceutical and biotechnology industries, in recognition of companies and products that contribute to science and human health.

"These awards reflect our efforts to build a world-class research and development organization focused on bringing innovative and much-needed new medicines to patients around the world," says Robert R. Ruffolo, Jr., Ph.D., President, Wyeth Research, and Senior Vice President, Wyeth.

The Best Overall Pipeline award recognizes the importance of Wyeth's research and development within the pharmaceutical industry. With research and development programs spanning small molecules, biopharmaceuticals and vaccines, Wyeth is exploring more than 75 new therapies. These include novel approaches to fighting Alzheimer's disease, cancer and infectious disease, as well as innovative therapies for bone repair, osteoporosis and mental health disorders.

Wyeth received the Best New Drug award for TORISEL(TM) (temsirolimus), approved by the U.S. Food and Drug Administration in 2007 for patients with advanced renal cell carcinoma (RCC), a form of kidney cancer. This award is given to the product that represents the best therapeutic advance in its area. TORISEL is the first mTOR (mammalian target of rapamycin) inhibitor approved for
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
2. Wyeths Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health care
3. Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
4. Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
5. Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
6. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
7. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. Wyeth Consumer Healthcare Announces the Availability of Centrum Cardio and New Formula Centrum Products
10. Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
11. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension

Post Your Comments:

Wyeth Receives Honors at the 2007 Sc...( COLLEGEVILLE Pa. Dec. 5 /- WyethP...),Health